BRPI0611550A2 - uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto - Google Patents
uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com compostoInfo
- Publication number
- BRPI0611550A2 BRPI0611550A2 BRPI0611550-0A BRPI0611550A BRPI0611550A2 BR PI0611550 A2 BRPI0611550 A2 BR PI0611550A2 BR PI0611550 A BRPI0611550 A BR PI0611550A BR PI0611550 A2 BRPI0611550 A2 BR PI0611550A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- analogs
- isomers
- kit
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
USO DE UM COMPOSTO SELECIONADO DO GRUPO QUE CONSISTE EM ISâMEROS DE 4-HIDRàXI ISOLEUCINA, ANÁLOGOS DE 4- HIDRàXI ISOLEUCINA, E LACTONAS, SAIS, METABàLITOS, SOLVATOS E/OU PRà-MEDICAMENTOS FARMACEUTICAMENTE ACEITÁVEIS DOS DITOS ISâMEROS E ANÁLOGOS, COMPOSTO, KIT FARMACÊUTICO, COMPOSIÇçO FARMACÊUTICA, USO DO COMPOSTO E KIT COM COMPOSTO. A invenção refere-se a 4-hidróxi isoleucina, isômeros, análogos, lactonas, sais e pró-medicamentos da mesma, aos processos para a sua preparação, e às composições farmacêuticas que compreendem os mesmos. Mais particularmente, a invenção refere-se ao uso desses compostos na prevenção e no tratamento da obesidade e de síndromes correlatas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66403805P | 2005-03-22 | 2005-03-22 | |
PCT/IB2006/002400 WO2006131836A2 (en) | 2005-03-22 | 2006-03-22 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0611550A2 true BRPI0611550A2 (pt) | 2009-01-13 |
Family
ID=37498818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0611550-0A BRPI0611550A2 (pt) | 2005-03-22 | 2006-03-22 | uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060223884A1 (pt) |
EP (1) | EP1874287A2 (pt) |
JP (1) | JP2008538211A (pt) |
CN (1) | CN101252926A (pt) |
AU (1) | AU2006256442A1 (pt) |
BR (1) | BRPI0611550A2 (pt) |
CA (1) | CA2600954A1 (pt) |
WO (1) | WO2006131836A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101193852A (zh) * | 2005-02-18 | 2008-06-04 | 因诺迪亚有限公司 | 4-羟基异亮氨酸类似物及其用途 |
WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
JPWO2008044770A1 (ja) * | 2006-10-13 | 2010-02-18 | 味の素株式会社 | 4−ヒドロキシイソロイシンを含む胃排出抑制剤 |
EP2123629A1 (en) | 2007-02-22 | 2009-11-25 | Ajinomoto Co., Inc. | Method for purifying 4-hydroxyisoleucine |
US8143014B2 (en) | 2007-10-02 | 2012-03-27 | Mayo Foundation For Medical Education And Research | CD38 and obesity |
CA2799157A1 (en) * | 2009-05-06 | 2010-11-11 | Xianqi Kong | Ammo acid derivatives for the treatment of neuropathic pain |
JP5703654B2 (ja) * | 2010-09-22 | 2015-04-22 | 東レ・ファインケミカル株式会社 | シス−4−ヒドロキシプロリンの製造法 |
MX2014014138A (es) | 2012-05-22 | 2015-02-24 | Actelion Pharmaceuticals Ltd | Procedimiento nuevo para la preparacion de acido 2-ciclopentil-6-metoxi-isonicotinico. |
CN107998024A (zh) * | 2017-12-20 | 2018-05-08 | 上海东晟源日化有限公司 | 一种含仙人掌精华具有深度保养功效的护肤用品 |
CN112089710B (zh) * | 2020-08-07 | 2022-04-01 | 郑州大学 | 4-羟基异亮氨酸在制备抗肿瘤药物中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63218621A (ja) * | 1987-03-09 | 1988-09-12 | Kazuoki Tsuchiya | 肥満症の予防・治療用組成物 |
US4912231A (en) * | 1987-06-15 | 1990-03-27 | E. R. Squibb & Sons, Inc. | Process for preparing (trans)-4-phenyl-L-proline derivatives |
FR2695317B1 (fr) * | 1992-09-07 | 1995-03-10 | Monal Lab | Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant. |
IL108583A (en) * | 1994-02-07 | 1997-06-10 | Yissum Res Dev Co | Galactomannan emulsions and comestible products containing the same |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
CA2206157C (en) * | 1997-05-26 | 2000-06-13 | Cheng, Peter | Method of extraction of commercially valuable fractions of fenugreek |
WO1999025370A1 (en) * | 1997-11-18 | 1999-05-27 | Nutricept, Inc. | Methods for reducing the intestinal absorption of a caloric of compound in diabetics |
UA59453C2 (uk) * | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
FR2797767B1 (fr) * | 1999-08-27 | 2002-06-14 | Centre Nat Rech Scient | Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances |
IN192689B (pt) * | 2000-02-14 | 2004-05-15 | Rao Gariimella Bhaskar Dr | |
FR2806726B1 (fr) * | 2000-03-27 | 2003-01-03 | Centre Nat Rech Scient | Procede de preparation de la (2s,3r,4s)-4-hydroxyisoleucine et de ses analogues |
US6903136B2 (en) * | 2002-04-22 | 2005-06-07 | Experimental And Applied Sciences, Inc. | Food supplements containing 4-hydroxyisoleucine and creatine |
US20050176827A1 (en) * | 2002-05-10 | 2005-08-11 | Lee Steve S. | Compositions and methods for glycogen synthesis |
US7338675B2 (en) * | 2002-05-10 | 2008-03-04 | Tsi Health Sciences, Inc. | Fenugreek seed bio-active compositions and methods for extracting same |
US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
JPWO2004083179A1 (ja) * | 2003-03-19 | 2006-06-22 | 協和醗酵工業株式会社 | 糖尿病治療剤 |
KR20050106528A (ko) * | 2003-03-28 | 2005-11-09 | 교와 핫꼬 고교 가부시끼가이샤 | 항비만제 |
FR2854629B1 (fr) * | 2003-05-07 | 2005-06-17 | Centre Nat Rech Scient | Procede de synthese de la 4-hydroxyisoleucine et de ses derives |
DK1638586T3 (da) * | 2003-05-14 | 2008-06-23 | Indus Biotech Pvt Ltd | Synergistisk sammensætning til behandling af diabetes mellitus |
FR2856297B1 (fr) * | 2003-06-18 | 2005-08-05 | Caster | Utilisation de (2s,3r,4s)-4-hydroxyisoleucine dans des compositions cosmetiques pour application topique |
US20070004623A1 (en) * | 2003-10-27 | 2007-01-04 | Innodia Inc. | Use of hydroxylated amino acids for treating diabetes |
TW200528440A (en) * | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
US8337915B2 (en) * | 2004-01-10 | 2012-12-25 | S George Aburdeineh | Fenugreek seed extract to lower blood cholesterol |
ZA200605526B (en) * | 2004-02-12 | 2007-11-28 | Transtech Pharma Inc | Substituted azole derivatives, compositions and methods of use |
US20050233014A1 (en) * | 2004-03-02 | 2005-10-20 | Lee Steve S | Methods for affecting homeostasis and metabolism in a mammalian body |
US20050226948A1 (en) * | 2004-03-02 | 2005-10-13 | Lee Steve S | Methods for enhancing the transport of glucose into muscle |
US20050233013A1 (en) * | 2004-03-02 | 2005-10-20 | Lee Steve S | Methods for enhancing the transport of glucose for balancing blood sugar levels |
AU2006242851A1 (en) * | 2005-02-18 | 2006-11-09 | Centre National De La Recherche Scientifique (C.N.R.S.) | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
CN101193852A (zh) * | 2005-02-18 | 2008-06-04 | 因诺迪亚有限公司 | 4-羟基异亮氨酸类似物及其用途 |
-
2006
- 2006-03-22 WO PCT/IB2006/002400 patent/WO2006131836A2/en active Application Filing
- 2006-03-22 CA CA002600954A patent/CA2600954A1/en not_active Abandoned
- 2006-03-22 EP EP06779982A patent/EP1874287A2/en not_active Withdrawn
- 2006-03-22 US US11/387,534 patent/US20060223884A1/en not_active Abandoned
- 2006-03-22 BR BRPI0611550-0A patent/BRPI0611550A2/pt not_active IP Right Cessation
- 2006-03-22 AU AU2006256442A patent/AU2006256442A1/en not_active Abandoned
- 2006-03-22 JP JP2008502519A patent/JP2008538211A/ja active Pending
- 2006-03-22 CN CNA2006800176430A patent/CN101252926A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2600954A1 (en) | 2006-12-14 |
AU2006256442A1 (en) | 2006-12-14 |
JP2008538211A (ja) | 2008-10-16 |
WO2006131836A2 (en) | 2006-12-14 |
WO2006131836A3 (en) | 2007-10-04 |
CN101252926A (zh) | 2008-08-27 |
US20060223884A1 (en) | 2006-10-05 |
EP1874287A2 (en) | 2008-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0611550A2 (pt) | uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto | |
BRPI0508540B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0619153A8 (pt) | derivados de 4-aminopirroltriazina substituída, e composição farmacêutica | |
BRPI0706992C1 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BR112012010706A2 (pt) | composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio | |
BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
BR112014010206B8 (pt) | composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto | |
BRPI0507198A (pt) | derivados de bisariluréia | |
HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
BRPI0720972B8 (pt) | compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos | |
BRPI1007092B8 (pt) | Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato | |
BR112015032623A2 (pt) | composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação | |
CL2008003407A1 (es) | Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1. | |
BRPI0914536A8 (pt) | Tiadiazoliloxifenilamidinas, processo para sua preparação e seus usos, composição e processo para combater microorganismos indesejáveis, e semente resistente a microorganismos indesejáveis | |
CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
BRPI0520669A2 (pt) | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina | |
BRPI0821855B8 (pt) | composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
BRPI0519280A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto | |
CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
CL2008000959A1 (es) | Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c. | |
BRPI0617654B8 (pt) | composto, composição farmacêutica e processo para preparar o composto | |
BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
PT103884A (pt) | Composições de libertação prolongada e métodos para a sua preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |